4.5 Article

Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease

期刊

PARKINSONISM & RELATED DISORDERS
卷 28, 期 -, 页码 137-140

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2016.04.026

关键词

Parkinson; Subtypes; Clusters; Non-motor; Heterogeneity

资金

  1. Michael J. Fox Foundation for Parkinson's Research
  2. Abbvie
  3. Avid
  4. Biogen Idec
  5. Bristol-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genentech
  9. Glaxo Smith Kline
  10. Lilly
  11. Lundbeck
  12. Merck
  13. MSD
  14. Pfizer
  15. Piramal
  16. Roche
  17. UCB

向作者/读者索取更多资源

Background: The heterogeneity of PD suggests the existence of different subtypes. While some motor clusters have been consistently identified, little is known about non-motor PD subtypes and motor-non motor interplay. Research in this regard has produced somewhat contradictory results, which might be biased by the inclusion of treated patients. Patients and methods: We performed a non-hierarchical cluster analysis using both motor and non motor data on 398 newly diagnosed untreated PD patients enrolled in the Parldnson's Progressive Marker Initiative (PPMI) study. We further evaluated whether dopaminergic dysfunction, as measured by (123)[I]-FP-CIT SPECT scan, could explain, at least partially, the observed difference between the clusters. Results: Three clusters were identified. Group 1 was characterized by the lowest motor and non-motor burden, whereas group 2 and 3 had similar motor disability, but different non-motor involvement, especially with regards to apathy and hallucinations. (123)[I]-FP-CIT binding values paralleled motor disability burden among the 3 clusters, but further multivariate analyses also revealed a negative correlation with depression. Discussion: Our results confirm the motor as well as non-motor heterogeneity of PD, suggesting the existence of 3 different subtypes. Dopaminergic dysfunction only marginally explains the non-motor variability of PD. Identification of such clusters can have important implications for generating novel pathophysiological hypotheses and therapeutic strategies. (C) 2016 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据